Sunday 18 October 2026
Export NUWE’s income statement to Excel — free account
Nuwellis, Inc.
NUWE Healthcare Medical Devices
Nuwellis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.3 million, down 5.38% from fiscal 2024. In the quarter to June 2026, revenue grew 14.1%, EPS grew 98.8% and free cash flow fell 51.6%, each against the same quarter a year earlier.
0.55
0.00
0.00%
Follow NUWE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 4 |
+8 more TTM periods Free account |
| 205.50% | (610.45%) | (382.80%) | (467.58%) | ||
| (123.52%) | (272.69%) | (219.21%) | (225.18%) | ||
ROIC |
0.00% | (1,345.35%) | (449.27%) | (848.43%) | |
Return on Tangible Assets |
(267.06%) | (773.48%) | (694.57%) | (404.79%) | |
Average Days of Receivables |
62.57 | 64.89 | 65.89 | 50.99 | |
Free Cash Flow per Share |
(69.97) | (195.55) | (554.47) | (393.01) | |
Free Cash Flow |
(12.68) | (11.60) | (10.92) | (9.39) | |
Capital Expenditures |
(0.21) | (0.21) | (0.11) | (0.11) | |
| Other line items | |||||
Cash ROIC |
(675.49%) | (244.02%) | (294.02%) | (134.15%) | |
Accounts Receivable Turnover |
6.58 | 5.66 | 5.14 | 6.71 | |
Accounts Payable Turnover |
0.93 | 1.46 | 1.63 | 1.49 | |
Inventory Turnover |
1.45 | 1.72 | 1.73 | 1.65 | |
Average Days of Payables |
386.91 | 292.80 | 258.26 | 291.30 | |
Days of Inventory on Hand |
232.73 | 214.44 | 221.60 | 239.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
46.12% | 44.36% | 32.79% | 32.55% | |
Selling, General and Administrative Expense of Revenue |
166.44% | 164.96% | 163.46% | 161.80% | |
Share Based Compensation of Revenue |
1.00% | 0.97% | 1.54% | 2.53% | |
Interest Coverage |
(0.58) | — | — | — | |
Operating CF/Net income |
1.10 | 0.60 | 0.62 | 0.56 | |
Depreciation/Fixed assets |
0.44 | 0.45 | 0.54 | 0.63 | |
Capex/Depreciation |
(1.41) | (1.27) | (0.56) | (0.42) | |
Revenue per Share |
49.74 | 147.88 | 419.80 | 341.76 | |
Operating CF per Share |
(68.79) | (192.01) | (548.73) | (388.45) | |
Capex per Share |
(1.19) | (3.54) | (5.74) | (4.56) | |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.01 |
Columns are period end dates